- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02135042
Geïndividualiseerde behandeling bij de behandeling van patiënten met stadium II-IVB nasofarynxcarcinoom op basis van EBV-DNA
Gerandomiseerde fase II- en fase III-studies van geïndividualiseerde behandeling van nasofarynxcarcinoom op basis van biomarker Epstein Barr-virus (EBV) Desoxyribonucleïnezuur (DNA)
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
- Geneesmiddel: Paclitaxel
- Ander: Laboratory Biomarker Analysis
- Ander: Quality-of-Life Assessment
- Geneesmiddel: Cisplatin
- Geneesmiddel: Fluorouracil
- Procedure: Magnetic Resonance Imaging
- Geneesmiddel: Gemcitabine Hydrochloride
- Procedure: Computed Tomography
- Procedure: Positron Emission Tomography
- Procedure: Bone Scan
- Straling: Intensity-Modulated Radiation Therapy
- Ander: Clinical Observation
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. To determine whether substituting adjuvant concurrent high dose cisplatin (CDDP) and fluorouracil (5-FU) with gemcitabine (gemcitabine hydrochloride) and paclitaxel will result in superior progression-free survival. (Detectable Plasma Epstein Barr Virus [EBV] Deoxyribonucleic Acid [DNA] Cohort randomized Phase II) II. To determine whether omitting adjuvant CDDP and 5-FU (observation alone in the adjuvant setting) will result in non-inferior overall survival as compared with those patients receiving adjuvant CDDP and 5-FU chemotherapy. (Undetectable Plasma EBV DNA Cohort Phase III)
SECONDARY OBJECTIVES:
I. Time to distant metastasis. (Randomized Phase II and Phase III) II. Time to local progression. (Randomized Phase II and Phase III) III. Time to regional progression. (Randomized Phase II and Phase III) IV. Progression-free survival (Undetectable Cohort). V. Overall survival (Detectable Cohort). VI. Acute and late toxicity profiles based on clinician-reported Common Terminology Criteria for Adverse Events (CTCAE), version (v.) 4. (Randomized Phase II and Phase III) VII. Death during or within 30 days of end of protocol treatment. (Randomized Phase II and Phase III) VIII. Quality of life (general and physical well-being). (Randomized Phase II and Phase III) IX. Quality of life (hearing). (Randomized Phase II and Phase III) X. Quality of life (peripheral neuropathy). (Randomized Phase II and Phase III) XI. Cost effectiveness. (Randomized Phase II and Phase III)
OUTLINE:
Patients undergo intensity modulated radiation therapy (IMRT) once daily (QD) 5 days a week for 6.5 to 7 weeks and receive low-dose cisplatin intravenously (IV) over 30-60 minutes or high-dose cisplatin IV over 3 hours once weekly during IMRT. Beginning 1 week after chemoradiation, plasma samples are collected for EBV DNA analysis.
PHASE II: Patients with detectable EBV DNA from pre-treatment analysis are randomized to 1 of 2 treatment arms.
ARM I: Patients receive PF regimen comprising cisplatin IV over 60-180 minutes and fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive GT regimen comprising paclitaxel IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 at least 4 weeks after completion of IMRT. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
PHASE III:
Patients with undetectable EBV DNA from pre-treatment analysis are randomized to 1 of 2 treatment arms.
ARM III: Patients receive PF regimen as in Arm I.
ARM IV: Patients undergo clinical observation.
Patients undergo computed tomography (CT) scan, magnetic resonance imaging, (MRI) positron emission tomography (PET) scan, and bone scan throughout the study.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Victoria
-
Melbourne, Victoria, Australië, 3000
- Peter MacCallum Cancer Centre
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Arthur J E Child Comprehensive Cancer Centre
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
Ontario
-
London, Ontario, Canada, N6A 4L6
- London Regional Cancer Program
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Jewish General Hospital
-
Montreal, Quebec, Canada, H3H 2R9
- The Research Institute of the McGill University Health Centre (MUHC)
-
Montreal, Quebec, Canada, H2W 1S6
- McGill University Department of Oncology
-
-
-
-
-
Guangzhou, China, 510060
- Sun Yat-sen University Cancer Center
-
-
Shanghai Municipality
-
Guangdong Province, Shanghai Municipality, China, 200032
- Zhongshan Hospital Fudan University
-
-
-
-
-
Chai Wan, Hongkong
- Pamela Youde Nethersole Eastern Hospital
-
Shatin, Hongkong
- Chinese University of Hong Kong-Prince of Wales Hospital
-
-
-
-
-
San Juan, Puerto Rico, 00927
- Centro Comprensivo de Cancer de UPR
-
-
-
-
-
Singapore, Singapore, 168583
- National Cancer Centre Singapore
-
-
-
-
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
Taoyuan, Taiwan, 33333
- Chang Gung Hospital-Lin Kou Medical Center
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35233
- University of Alabama at Birmingham Cancer Center
-
Birmingham, Alabama, Verenigde Staten, 35243
- The Kirklin Clinic at Acton Road
-
-
Arizona
-
Tucson, Arizona, Verenigde Staten, 85719
- Banner University Medical Center - Tucson
-
-
California
-
Auburn, California, Verenigde Staten, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Berkeley, California, Verenigde Staten, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Burlingame, California, Verenigde Staten, 94010
- Mills-Peninsula Medical Center
-
Cameron Park, California, Verenigde Staten, 95682
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park
-
Duarte, California, Verenigde Staten, 91010
- City of Hope Comprehensive Cancer Center
-
Dublin, California, Verenigde Staten, 94568
- Kaiser Permanente Dublin
-
Fresno, California, Verenigde Staten, 93720
- Fresno Cancer Center
-
La Jolla, California, Verenigde Staten, 92093
- UC San Diego Moores Cancer Center
-
Modesto, California, Verenigde Staten, 95355
- Memorial Medical Center
-
Oakland, California, Verenigde Staten, 94611
- Kaiser Permanente Oakland-Broadway
-
Orange, California, Verenigde Staten, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Verenigde Staten, 94304
- Stanford Cancer Institute Palo Alto
-
Palo Alto, California, Verenigde Staten, 94301
- Palo Alto Medical Foundation Health Care
-
Rancho Cordova, California, Verenigde Staten, 95670
- Kaiser Permanente-Rancho Cordova Cancer Center
-
Rohnert Park, California, Verenigde Staten, 94928
- Rohnert Park Cancer Center
-
Roseville, California, Verenigde Staten, 95678
- The Permanente Medical Group-Roseville Radiation Oncology
-
Roseville, California, Verenigde Staten, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Sacramento, California, Verenigde Staten, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Verenigde Staten, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Verenigde Staten, 95823
- South Sacramento Cancer Center
-
San Francisco, California, Verenigde Staten, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, Verenigde Staten, 94115
- California Pacific Medical Center-Pacific Campus
-
San Francisco, California, Verenigde Staten, 94115
- UCSF Medical Center-Mount Zion
-
Santa Clara, California, Verenigde Staten, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
South Pasadena, California, Verenigde Staten, 91030
- City of Hope South Pasadena
-
South San Francisco, California, Verenigde Staten, 94080
- Kaiser Permanente Cancer Treatment Center
-
Sunnyvale, California, Verenigde Staten, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
-
Colorado
-
Golden, Colorado, Verenigde Staten, 80401
- Lutheran Hospital - Cancer Centers of Colorado
-
Greeley, Colorado, Verenigde Staten, 80631
- Banner North Colorado Medical Center
-
Loveland, Colorado, Verenigde Staten, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Parker, Colorado, Verenigde Staten, 80138
- AdventHealth Parker
-
Wheat Ridge, Colorado, Verenigde Staten, 80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06520
- Yale University
-
-
Delaware
-
Newark, Delaware, Verenigde Staten, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Verenigde Staten, 19718
- Christiana Care Health System-Christiana Hospital
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32207
- Baptist MD Anderson Cancer Center
-
Tampa, Florida, Verenigde Staten, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Verenigde Staten, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Verenigde Staten, 30342
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, Verenigde Staten, 30308
- Emory Proton Therapy Center
-
-
Hawaii
-
Honolulu, Hawaii, Verenigde Staten, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Verenigde Staten, 96817
- The Cancer Center of Hawaii-Liliha
-
‘Aiea, Hawaii, Verenigde Staten, 96701
- The Cancer Center of Hawaii-Pali Momi
-
-
Idaho
-
Boise, Idaho, Verenigde Staten, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
-
Illinois
-
Aurora, Illinois, Verenigde Staten, 60504
- Rush-Copley Medical Center
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern University
-
Chicago, Illinois, Verenigde Staten, 60612
- John H Stroger Jr Hospital of Cook County
-
Decatur, Illinois, Verenigde Staten, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Verenigde Staten, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Verenigde Staten, 62401
- Crossroads Cancer Center
-
Springfield, Illinois, Verenigde Staten, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Verenigde Staten, 61801
- Carle Cancer Center
-
-
Indiana
-
South Bend, Indiana, Verenigde Staten, 46601
- Memorial Hospital of South Bend
-
-
Iowa
-
Des Moines, Iowa, Verenigde Staten, 50309
- Iowa Methodist Medical Center
-
Iowa City, Iowa, Verenigde Staten, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kansas
-
Wichita, Kansas, Verenigde Staten, 67214
- Ascension Via Christi Hospitals Wichita
-
Wichita, Kansas, Verenigde Staten, 67214
- Wesley Medical Center
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Verenigde Staten, 21204
- Greater Baltimore Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02111
- Tufts Medical Center
-
Boston, Massachusetts, Verenigde Staten, 02118
- Boston Medical Center
-
Boston, Massachusetts, Verenigde Staten, 02114
- Massachusetts General Hospital Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Verenigde Staten, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Bay City, Michigan, Verenigde Staten, 48706
- McLaren Cancer Institute-Bay City
-
Brownstown, Michigan, Verenigde Staten, 48183
- Henry Ford Cancer Institute-Downriver
-
Canton, Michigan, Verenigde Staten, 48188
- Trinity Health Medical Center - Canton
-
Clarkston, Michigan, Verenigde Staten, 48346
- McLaren Cancer Institute-Clarkston
-
Clinton Township, Michigan, Verenigde Staten, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Detroit, Michigan, Verenigde Staten, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Verenigde Staten, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Verenigde Staten, 48334
- Weisberg Cancer Treatment Center
-
Flint, Michigan, Verenigde Staten, 48532
- McLaren Cancer Institute-Flint
-
Flint, Michigan, Verenigde Staten, 48532
- Singh and Arora Hematology Oncology PC
-
Lansing, Michigan, Verenigde Staten, 48912
- Mid-Michigan Physicians-Lansing
-
Lansing, Michigan, Verenigde Staten, 48910
- Karmanos Cancer Institute at McLaren Greater Lansing
-
Lansing, Michigan, Verenigde Staten, 48912
- University of Michigan Health - Sparrow Lansing
-
Lapeer, Michigan, Verenigde Staten, 48446
- McLaren Cancer Institute-Lapeer Region
-
Livonia, Michigan, Verenigde Staten, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Mount Clemens, Michigan, Verenigde Staten, 48043
- McLaren Cancer Institute-Macomb
-
Mount Pleasant, Michigan, Verenigde Staten, 48858
- McLaren Cancer Institute-Central Michigan
-
Petoskey, Michigan, Verenigde Staten, 49770
- McLaren Cancer Institute-Northern Michigan
-
Pontiac, Michigan, Verenigde Staten, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Port Huron, Michigan, Verenigde Staten, 48060
- McLaren-Port Huron
-
Saginaw, Michigan, Verenigde Staten, 48601
- MyMichigan Medical Center Saginaw
-
West Bloomfield, Michigan, Verenigde Staten, 48322
- Henry Ford West Bloomfield Hospital
-
-
Minnesota
-
Burnsville, Minnesota, Verenigde Staten, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Verenigde Staten, 55337
- Minnesota Oncology - Burnsville
-
Fridley, Minnesota, Verenigde Staten, 55432
- Unity Hospital
-
Maplewood, Minnesota, Verenigde Staten, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Verenigde Staten, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Abbott-Northwestern Hospital
-
Robbinsdale, Minnesota, Verenigde Staten, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, Verenigde Staten, 55905
- Mayo Clinic in Rochester
-
Saint Paul, Minnesota, Verenigde Staten, 55101
- Regions Hospital
-
Willmar, Minnesota, Verenigde Staten, 56201
- Rice Memorial Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Verenigde Staten, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, Verenigde Staten, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Verenigde Staten, 63141
- Siteman Cancer Center at West County Hospital
-
Rolla, Missouri, Verenigde Staten, 65401
- Phelps Health Delbert Day Cancer Institute
-
Springfield, Missouri, Verenigde Staten, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Verenigde Staten, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Verenigde Staten, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Verenigde Staten, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Verenigde Staten, 63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Butte, Montana, Verenigde Staten, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89106
- Radiation Oncology Centers of Nevada Central
-
Las Vegas, Nevada, Verenigde Staten, 89119
- Radiation Oncology Centers of Nevada Southeast
-
Reno, Nevada, Verenigde Staten, 89502
- Renown Regional Medical Center
-
Reno, Nevada, Verenigde Staten, 89503
- Saint Mary's Regional Medical Center
-
-
New Jersey
-
Basking Ridge, New Jersey, Verenigde Staten, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, Verenigde Staten, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Verenigde Staten, 07645
- Memorial Sloan Kettering Bergen
-
New Brunswick, New Jersey, Verenigde Staten, 08903
- Rutgers Cancer Institute of New Jersey
-
Newark, New Jersey, Verenigde Staten, 07101
- Rutgers New Jersey Medical School
-
-
New York
-
Brooklyn, New York, Verenigde Staten, 11219
- Maimonides Medical Center
-
Brooklyn, New York, Verenigde Staten, 11215
- New York-Presbyterian/Brooklyn Methodist Hospital
-
Commack, New York, Verenigde Staten, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Verenigde Staten, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Verenigde Staten, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Verenigde Staten, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
New York, New York, Verenigde Staten, 10035
- New York Proton Center
-
Rochester, New York, Verenigde Staten, 14642
- University of Rochester
-
Sleepy Hollow, New York, Verenigde Staten, 10591
- Memorial Sloan Kettering Sleepy Hollow
-
The Bronx, New York, Verenigde Staten, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Verenigde Staten, 10467
- Montefiore Medical Center - Moses Campus
-
Uniondale, New York, Verenigde Staten, 11553
- Memorial Sloan Kettering Nassau
-
-
Ohio
-
Akron, Ohio, Verenigde Staten, 44307
- Cleveland Clinic Akron General
-
Chardon, Ohio, Verenigde Staten, 44024
- Geauga Hospital
-
Cincinnati, Ohio, Verenigde Staten, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, Verenigde Staten, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Verenigde Staten, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Verenigde Staten, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Verenigde Staten, 43210
- Ohio State University Comprehensive Cancer Center
-
Elyria, Ohio, Verenigde Staten, 44035
- Mercy Cancer Center-Elyria
-
Mansfield, Ohio, Verenigde Staten, 44906
- Cleveland Clinic Cancer Center Mansfield
-
Sandusky, Ohio, Verenigde Staten, 44870
- North Coast Cancer Care
-
Strongsville, Ohio, Verenigde Staten, 44136
- Cleveland Clinic Cancer Center Strongsville
-
Sylvania, Ohio, Verenigde Staten, 43560
- ProMedica Flower Hospital
-
West Chester, Ohio, Verenigde Staten, 45069
- University of Cincinnati Cancer Center-West Chester
-
Westlake, Ohio, Verenigde Staten, 44145
- UHHS-Westlake Medical Center
-
Wooster, Ohio, Verenigde Staten, 44691
- Cleveland Clinic Wooster Family Health and Surgery Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Verenigde Staten, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Gresham, Oregon, Verenigde Staten, 97030
- Legacy Mount Hood Medical Center
-
Portland, Oregon, Verenigde Staten, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
-
Pennsylvania
-
Chadds Ford, Pennsylvania, Verenigde Staten, 19317
- Christiana Care Health System-Concord Health Center
-
Danville, Pennsylvania, Verenigde Staten, 17822
- Geisinger Medical Center
-
Lewisburg, Pennsylvania, Verenigde Staten, 17837
- Geisinger Medical Oncology-Lewisburg
-
Lewistown, Pennsylvania, Verenigde Staten, 17044
- Lewistown Hospital
-
Pottsville, Pennsylvania, Verenigde Staten, 17901
- Geisinger Cancer Services-Pottsville
-
West Reading, Pennsylvania, Verenigde Staten, 19611
- Reading Hospital
-
Wilkes-Barre, Pennsylvania, Verenigde Staten, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Boiling Springs, South Carolina, Verenigde Staten, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Greenville, South Carolina, Verenigde Staten, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Verenigde Staten, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Verenigde Staten, 29615
- Prisma Health Cancer Institute - Eastside
-
Greer, South Carolina, Verenigde Staten, 29650
- Prisma Health Cancer Institute - Greer
-
Greer, South Carolina, Verenigde Staten, 29651
- Gibbs Cancer Center-Pelham
-
Seneca, South Carolina, Verenigde Staten, 29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg, South Carolina, Verenigde Staten, 29303
- Spartanburg Medical Center
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Houston, Texas, Verenigde Staten, 77030
- UT MD Anderson Cancer Center
-
-
Utah
-
American Fork, Utah, Verenigde Staten, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City, Utah, Verenigde Staten, 84720
- Sandra L Maxwell Cancer Center
-
Logan, Utah, Verenigde Staten, 84321
- Logan Regional Hospital
-
Murray, Utah, Verenigde Staten, 84107
- Intermountain Medical Center
-
Ogden, Utah, Verenigde Staten, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, Verenigde Staten, 84604
- Utah Valley Regional Medical Center
-
Riverton, Utah, Verenigde Staten, 84065
- Riverton Hospital
-
Salt Lake City, Utah, Verenigde Staten, 84106
- Utah Cancer Specialists-Salt Lake City
-
St. George, Utah, Verenigde Staten, 84770
- Saint George Regional Medical Center
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Inova Schar Cancer Institute
-
Falls Church, Virginia, Verenigde Staten, 22042
- Inova Fairfax Hospital
-
Portsmouth, Virginia, Verenigde Staten, 23708-2197
- Naval Medical Center - Portsmouth
-
-
Washington
-
Vancouver, Washington, Verenigde Staten, 98686
- Legacy Salmon Creek Hospital
-
-
Wisconsin
-
Antigo, Wisconsin, Verenigde Staten, 54409
- Aspirus Cancer Care-Antigo-Volm Cancer Center
-
Eau Claire, Wisconsin, Verenigde Staten, 54701
- Marshfield Medical Center-EC Cancer Center
-
Eau Claire, Wisconsin, Verenigde Staten, 54701
- HSHS Sacred Heart Hospital
-
La Crosse, Wisconsin, Verenigde Staten, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Verenigde Staten, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield, Wisconsin, Verenigde Staten, 54449
- Marshfield Medical Center-Marshfield
-
Marshfield, Wisconsin, Verenigde Staten, 54449
- Marshfield Medical Center
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Medical College of Wisconsin
-
Minocqua, Wisconsin, Verenigde Staten, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Verenigde Staten, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Verenigde Staten, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Stevens Point, Wisconsin, Verenigde Staten, 54481
- Aspirus Cancer Care - Stevens Point
-
Wausau, Wisconsin, Verenigde Staten, 54401
- Aspirus Cancer Care-Wausau
-
Weston, Wisconsin, Verenigde Staten, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Verenigde Staten, 54494
- Aspirus Cancer Care - Wisconsin Rapids
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Biopsy proven (from primary lesion and/or lymph nodes) diagnosis of cancer of the nasopharynx
-
Sites are required to complete Step 1 registration before submitting specimens for EBV DNA analysis
- Patients must have detectable pretreatment plasma EBV DNA, determined by the central lab prior to Step 2 registration
- For patients who have detectable plasma EBV DNA tested at one of the credentialed central labs within 28 days prior to Step 1 registration: that test result can be used for eligibility without the need for re-testing; to use this test result for eligibility, the central lab must enter the test result through the pathology portal
-
Stage II-IVB disease (American Joint Committee on Cancer [AJCC], 7th edition [ed.]) with no evidence of distant metastasis, based upon the following minimum diagnostic workup:
-
History/physical examination by a Medical Oncologist or Clinical Oncologist or Radiation Oncologist or Ear, Nose, Throat specialist (ENT), which must include an endoscopic evaluation, a complete list of current medications, and assessment of weight and weight loss in the past 6 months within 21 days prior to registration
-
Evaluation of tumor extent required within 28 days prior to registration:
-
Magnetic resonance imaging (MRI) of the nasopharynx and neck; or computed tomography (CT) of the nasopharynx and neck with =< 3 mm contiguous slices with contrast and bone windows (to evaluate base of skull involvement).
- Note: If a treatment planning CT scan is used, it must be with =< 3 mm contiguous slices with contrast and be read by a radiologist
-
-
To rule out distant metastasis, patients must undergo the following imaging within 28 days prior to registration:
- A CT scan with contrast of the chest and abdomen (required), and the pelvis (optional), or a total body PET/CT scan (non-contrast PET/CT is acceptable)
- A bone scan only when there is suspicion of bone metastases (a PET/CT scan can substitute for the bone scan)
-
-
Zubrod performance status 0-1 within 21 days prior to registration
-
Age >= 18
-
Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (within 21 days prior to registration)
-
Platelets >= 100,000 cells/mm^3 (within 21 days prior to registration)
-
Hemoglobin >= 8.0 g/dl (within 21 days prior to registration) (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable)
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 21 days prior to registration)
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x institutional ULN (within 21 days prior to registration)
-
Alkaline phosphatase =< 1.5 x institutional ULN (within 21 days prior to registration)
-
Serum creatinine =< 1.5 mg/dl or calculated creatinine clearance (CC) >= 50 ml/min determined by 24-hour urine collection or estimated by Cockcroft-Gault formula (within 21 days prior to registration)
-
Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential
-
Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control throughout protocol treatment
-
Patient must provide study specific informed consent prior to study entry, including the mandatory pre-treatment plasma EBV DNA assay
Exclusion Criteria:
-
Prior invasive malignancy (except node negative, non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
-
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable; however, at least 6-weeks recovery is necessary if the last regimen included nitrosourea or mitomycin
-
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
-
Patients with hearing loss assessed to be primarily sensorineural in nature, requiring a hearing aid, or intervention (i.e. interfering in a clinically significant way with activities of daily living); a conductive hearing loss that is tumor-related is allowed
-
>= Grade 2 peripheral sensory neuropathy (CTCAE, v. 4.0)
-
Severe, active co-morbidity, defined as follows:
- Major medical or psychiatric illness, which in the investigator's opinion would interfere with the completion of therapy and follow up or with full understanding of the risks and potential complications of the therapy
- Unstable angina and/or uncontrolled congestive heart failure within past 6 months
- Myocardial infarction within the last 6 months
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; note that patients switched from IV antibiotics and currently on oral antibiotics whose infection is assessed to be adequately treated or controlled are eligible
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration
- Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
-
Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
-
Prior allergic reaction to the study drug(s) involved in this protocol
-
Patients with undetectable pre-treatment plasma EBV DNA
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Phase I, Arm I (chemoradiation, cisplatin, fluorouracil)
Patients receive PF regimen comprising cisplatin IV over 60-180 minutes and fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI,PET scan, and bone scan throughout the study. |
Correlative studies Ancillary studies
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Undergo MRI
Andere namen:
Undergo CT scan
Andere namen:
Undergo PET scan
Andere namen:
Undergo bone scan
Andere namen:
Undergo IMRT
Andere namen:
|
|
Experimenteel: Phase I, Arm II (chemoradiation, gemcitabine, paclitaxel)
Patients receive GT regimen comprising paclitaxel IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 at least 4 weeks after completion of IMRT. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI,PET scan, and bone scan throughout the study. |
Given IV
Andere namen:
Correlative studies Ancillary studies
Andere namen:
Given IV
Andere namen:
Undergo MRI
Andere namen:
Given IV
Andere namen:
Undergo CT scan
Andere namen:
Undergo PET scan
Andere namen:
Undergo bone scan
Andere namen:
Undergo IMRT
Andere namen:
|
|
Actieve vergelijker: Phase II, Arm III (chemoradiation, cisplatin, fluorouracil)
Patients receive PF regimen as in Arm I of Phase II.Patients undergo CT scan, MRI,PET scan, and bone scan throughout the study. |
Correlative studies Ancillary studies
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Undergo MRI
Andere namen:
Undergo CT scan
Andere namen:
Undergo PET scan
Andere namen:
Undergo bone scan
Andere namen:
Undergo IMRT
Andere namen:
|
|
Experimenteel: Phase II, Arm IV (chemoradiation, observation)
Patients undergo clinical observation. Patients undergo CT scan, MRI,PET scan, and bone scan throughout the study. |
Correlative studies Ancillary studies
Andere namen:
Given IV
Andere namen:
Undergo MRI
Andere namen:
Undergo CT scan
Andere namen:
Undergo PET scan
Andere namen:
Undergo bone scan
Andere namen:
Undergo IMRT
Andere namen:
Undergo clinical observation
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free survival (PFS) (Detectable Plasma Epstein Barr virus [EBV] deoxyribonucleic acid [DNA] Cohort Phase II)
Tijdsspanne: Up to 7 years
|
Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a 1-sided stratified log rank test. for stratification factors and concurrent cisplatin dose. A one-sided log rank test will be used to compare the PFS at a significance level of 0.1379. |
Up to 7 years
|
|
Overall survival (OS) (Undetectable Plasma EBV DNA Cohort Phase III)
Tijdsspanne: Up to 7 years
|
Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a 1-sided stratified log rank test. for stratification factors and concurrent cisplatin dose. The confidence interval approach will be used for the final analysis of OS. |
Up to 7 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to distant metastasis (DM) (Phase II and III)
Tijdsspanne: Up to 7 years
|
The cumulative incidence method will be used to estimate local, regional, and distant failure rates. The failure rates for the experimental treatment will be compared against the control using a failure-specific log-rank test. Multivariate analysis will be performed using the Cox proportional hazards model. |
Up to 7 years
|
|
Time to local progression (Phase II and III)
Tijdsspanne: Up to 7 years
|
The cumulative incidence method will be used to estimate local, regional, and distant failure rates. The failure rates for the experimental treatment will be compared against the control using a failure-specific log-rank test. Multivariate analysis will be performed using the Cox proportional hazards model. |
Up to 7 years
|
|
Time to regional progression (Phase II and III)
Tijdsspanne: Up to 7 years
|
Defined as an estimated increase in the size of the tumor (product of the perpendicular diameters of the two largest dimensions) of greater than 25%, taking as reference the smallest value of all previous measurements or appearance of new areas of malignant disease. The cumulative incidence method will be used to estimate local, regional, and distant failure rates. The failure rates for the experimental treatment will be compared against the control using a failure-specific log-rank test. Multivariate analysis will be performed using the Cox proportional hazards model. |
Up to 7 years
|
|
Progression-free survival (PFS) (Undetectable Plasma EBV DNA Cohort Phase III)
Tijdsspanne: Up to 7 years
|
Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a 1-sided stratified log rank test. for stratification factors and concurrent cisplatin dose. |
Up to 7 years
|
|
Overall survival (OS) (Detectable Plasma EBV DNA Cohort Phase II)
Tijdsspanne: Up to 7 years
|
Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a 1-sided stratified log rank test. for stratification factors and concurrent cisplatin dose. |
Up to 7 years
|
|
Incidence of acute grade 3-5 adverse events (Phase II and III)
Tijdsspanne: Up to 7 years
|
Rates of specific acute toxicity profiles and late toxicity profiles will be estimated using a binomial distribution along with their associated 95% confidence intervals and will be compared using Fisher's exact test between the 2 treatment arms. |
Up to 7 years
|
|
Incidence of late grade 3-5 adverse events (Phase II and III)
Tijdsspanne: Up to 7 years
|
Rates of specific acute toxicity profiles and late toxicity profiles will be estimated using a binomial distribution along with their associated 95% confidence intervals and will be compared using Fisher's exact test between the 2 treatment arms. |
Up to 7 years
|
|
Incidence of death (Phase II and III)
Tijdsspanne: Up to 30 days of end of protocol treatment
|
Incidence of death will be determined. |
Up to 30 days of end of protocol treatment
|
|
Changes in pure tone audiometry (Phase II and III)
Tijdsspanne: Baseline to up to 1 year
|
Correlation between categorical measures will be summarized by odds ratios, chi-square tests, and associated measures. Adjusted correlation may be derived from analysis of covariance (ANCOVA) models or derived directly using nonparametric analysis of variance (ANOVA) models if normality assumption is violated. Correlations between HHIE-S PRO scores and PTA and FACT-NP hearing, and PTA will be compared as dependent statistics |
Baseline to up to 1 year
|
|
Changes in quality of life (QOL) (general and physical well-being) (Phase II and III)
Tijdsspanne: Baseline to up to 24 months
|
Will be assessed using the Functional Assessment of Cancer Therapy (FACT)-Nasopharyngeal (NP). Changes in patient reported outcome (PRO) scores will be correlated to clearance or non-clearance of EBV titers. Descriptive statistics derived from FACT-NP will be used to enrich the understanding of QOL as it pertains to the 2 phase III arms of observation versus additional adjuvant chemotherapy. Univariable and multivariable analysis will be performed using the Cox proportional hazards model for OS and distant metastasis. Pearson correlation will be estimated between general and physical well-being. QOL measures and change from baseline will be correlated to EBV DNA. |
Baseline to up to 24 months
|
|
Changes in quality of life (QOL) (hearing) (Phase II and III)
Tijdsspanne: Baseline to up to 24 months
|
Will be assessed by the Hearing Handicap Inventory for the Elderly-Screening version (HHIE-S). QOL analysis including overall score and change from baseline will be summarized using mean and standard deviation at each time point for each arm. Overall and nasopharyngeal-specific QOL, hearing QOL (FACT-NP hearing domain, HHIE-S scores), peripheral neuropathy QOL over the short and long term and pure-tone audiometry (PTA) scores will be compared using a two sample independent t test and paired t test if the comparison is within the experimental arm between different time points. |
Baseline to up to 24 months
|
|
Changes in quality of life (QOL) (peripheral neuropathy) as assessed by the Functional Assessment of Cancer Therapy (FACT)-Taxane (Phase II and III)
Tijdsspanne: Baseline to up to 24 months
|
Changes in QOL (peripheral neuropathy) will be assessed by the Functional Assessment of Cancer Therapy (FACT)-Taxane. |
Baseline to up to 24 months
|
|
Cost effectiveness as assessed by the health-related quality of life (QOL) (HRQOL) from the EuroQol (EQ-5D) instrument (Phase II and III)
Tijdsspanne: Up to 24 months
|
Incremental cost effectiveness ratios will be compared to determine the probability of cost effectiveness of various interventions, with sensitivity analyses to identify model weaknesses. The expected value of perfect information will be determined to delimit the upper boundary for cost-effective future investment in this area of research. |
Up to 24 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Nancy Y Lee, NRG Oncology
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Stomatognatische ziekten
- Neoplasmata per site
- Neoplasmata
- Infecties
- Virusziekten
- Neoplasmata per histologisch type
- Hoofd- en nekneoplasmata
- Neoplasmata, glandulair en epitheel
- DNA-virusinfecties
- Carcinoom
- KNO-ziekten
- Faryngeale neoplasmata
- Otorinolaryngologische neoplasmata
- Nasofaryngeale ziekten
- Faryngeale ziekten
- Herpesviridae-infecties
- Tumorvirusinfecties
- Nasofaryngeale neoplasmata
- Nasofarynxcarcinoom
- Epstein-Barr-virusinfecties
- Health Services Administration
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Onderzoekstechnieken
- Methoden
- Therapeutica
- Koolwaterstoffen
- Cycloparaffins
- Koolwaterstoffen, alicyclisch
- Koolwaterstoffen, cyclisch
- Terpenen
- Kwaliteit van de gezondheidszorg
- Anorganische chemicaliën
- Chloorverbindingen
- Stikstofverbindingen
- Taxoids
- Cyclodecanes
- Diterpenen
- Deoxycytidine
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Elementen
- Metalen
- Gezondheidszorg economie en organisaties
- Chemie -technieken, analytisch
- Spectrumanalyse
- Uracil
- Pyrimidinonen
- Metalen, zwaar
- Platinumverbindingen
- Radiotherapie
- Uitkomstbeoordeling, gezondheidszorg
- Uitkomst en procesbeoordeling, gezondheidszorg
- Overgangselementen
- Radiotherapie, conform
- Radiotherapie, computerondersteund
- Economie
- Gemcitabine
- Fluorouracil
- Paclitaxel
- Cisplatine
- 1,2-diaminocyclohexaanplatina II-citraat
- Observatie
- Magnetische resonantiespectroscopie
- Waakzaam wachten
- Platina
- Radiotherapie, intensiteit gemoduleerd
- Dehydroforafur
- Belastingen
Andere studie-ID-nummers
- NRG-HN001
- U10CA180868 (Subsidie/contract van de Amerikaanse NIH)
- U10CA021661 (Subsidie/contract van de Amerikaanse NIH)
- NRG-HN001 (Andere identificatie: CTEP)
- NCI-2014-00635 (Register-ID: CTRP (Clinical Trial Reporting Program))
- s16-00025
- RTOG-1305
- NRG-HN001 (Andere identificatie: NRG Oncology)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .